Novartis

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends …

Pharma Isn’t Eager To Carry Cures Act 2.0 Over Finish Line Despite Being Instrumental In Passage Of First Version | Kaiser Health News | 12/4/2019

… pushing the administration to reduce the length of time that leading biologic drugs would be protected from generic imitators in the U.S.-Mexico-Canada Agreement, or USMCA. (Mauldin, Andrews and Leary, 12/2) Reuters: Pfizer, Novartis Lead $2 Billion Spending Spree On Gene Therapy Production Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters …

Follow Novartis:    

Novartis taps Amazon to build data analytics platform | Becker’s Hospital Review | 12/4/2019

… Services to develop a cloud-based data analytics platform to improve the pharmaceutical company’s manufacturing, supply chain and delivery operations, according to a Dec. 4 Amazon blog post. The multiyear collaboration will focus on Novartis Insight Centers, which provide real-time data insights of manufacturing operations and distribution centers across its network. Leveraging AWS, Novartis can collect inventory, quality and production data across its network and apply the cloud platform’s …

MDCO, IPHS, BREW, and CARB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts | Benzinga | 12/4/2019

WILMINGTON, Del., Rigrodsky & Long, P.A. announces that it is investigating: The Medicines Company (NASDAQ GS: MDCO ) regarding possible breaches of fiduciary duties and other violations of law related to The Medicines Company’s agreement to be acquired by Novartis AG. Shareholders of The Medicines Company will receive $85.00 in cash for each share of The Medicines Company owned. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases …

MDCO, IPHS, BREW, and CARB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts | Globe Newswire | 12/4/2019

WILMINGTON, Del., Rigrodsky & Long, P.A. announces that it is investigating: The Medicines Company (NASDAQ GS: MDCO ) regarding possible breaches of fiduciary duties and other violations of law related to The Medicines Company’s agreement to be acquired by Novartis AG. Shareholders of The Medicines Company will receive $85.00 in cash for each share of The Medicines Company owned. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases …

Erwin S. F. Vanhaecke, PhD, Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who’s Who | 12/4/2019

Dr. Vanhaecke has been endorsed by Marquis Who’s Who as a leader in the pharmaceutical industry Dr. Erwin S. F. Vanhaecke is most proud of his work in building quality and brand reputation in a short time as global head of Novartis Quality. ALEDO, TX, December 04, Marquis Who’s Who, the world’s premier publisher of biographical profiles, is proud to present Erwin Vanhaecke, PhD, with the Albert Nelson Marquis Lifetime …

AWS Announces Strategic Collaboration with Novartis to Accelerate Digital Transformation of Its Business Operations | Business Wire | 12/4/2019

SEATTLE–(BUSINESS WIRE)–Dec 4, 2019– Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), announced a multi-year strategic collaboration with Novartis to reimagine this leading pharmaceutical company’s core pharmaceutical manufacturing, supply chain, and delivery operations using AWS’s portfolio of cloud services. This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help …

W2O Appoints Biopharma and Digital Marketing Leaders Jonathan Peacock and George Gallate to Board of Directors to Increase Competitive Edge and Drive Global Growth | Business Wire | 12/4/2019

… and on an international scale. Peacock has more than three decades of C-suite experience in the pharmaceutical, emerging biotech and corporate financial industries. He has held global chief financial officer (CFO) roles at Novartis and Amgen, as well as leadership positions in strategy and corporate finance at McKinsey & Company and PricewaterhouseCoopers. Gallate is rejoining the W2O board of directors. He has more than 30 years of experience in building …

Global Anti-infective Drugs Market Report 2019 with Forecasts to 2024, Led by Novartis, Merck & Co, Sanofi, GSK, and Gilead Sciences - ResearchAndMarkets.com | Business Wire | 12/4/2019

… channels as well as reaching out to each category of patients with different diseases and age groups, which makes the companies grow in this market. Some of the major players in the market are Novartis AG, Merck & Co., Inc, Sanofi SA, GSK, and Gilead Sciences, among others. Key Topics Covered 1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 …

First Industry Datasets Submitted to ASH Research Collaborative Data Hub | PR Newswire | 12/4/2019

WASHINGTON , Dec. 4, The ASH Research Collaborative (ASH RC) has collaborated with two industry leaders, Novartis Pharmaceuticals Corporation (Novartis) and Amgen, to include de-identified patient data from three separate studies of nearly 500 patients living with Sickle Cell Disease (SCD) and more than 1,000 patients with multiple myeloma as part of an unprecedented data sharing initiative. Novartis and Amgen are the first two pharmaceutical companies to provide datasets to …

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2024 - Therapeutics by HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors and Hormone Receptors | PR Newswire | 12/4/2019

… Pipeline by Phase Phase III Phase II Phase I Pipeline by Company AbbVie Inc. Array BioPharma Inc. AstraZeneca Belrose Pharmaceuticals Beta Pharma BioMarin Pharmaceuticals CASI Pharmaceuticals Inc. Celgene Celldex Therapeutics Celsion Clovis Eli Lilly Novartis Pfizer Puma Biotechnology Roche Syndax Pharmaceuticals Tesaro Inc. Chapter 13 Competitive Landscape Major Mammography Equipment Market Players Major Breast Cancer Drug Market Players Chapter 14 Company Profiles Abbvie Inc. Abbott Laboratories Astrazeneca Plc Atossa Genetics …

Novartis Associate Job Opening – BSc Biotech/Biochem/Biology Apply Online | 12/4/2019

Business Unit : Product Dev SZ Employment Type : Regular Job Description for Novartis Job: The key responsibility of this position is to ensure: Support DRC Manager/ Specialist for Regulatory filings/dossiers as per established development milestones. Take project ownership within DRC for projects with a reduced degree of complexity as well as supports DRC Manager/Specialist for higher complexity projects. Prompt regulatory authorization is obtained by appropriate Health Authorities. Your obligations …

FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray | 12/4/2019

staff reporter NEW YORK – Foundation Medicine said on Wednesday that the US Food and Drug Administration has approved its FoundationOne CDx test as a companion diagnostic for alpelisib (Novartis’ Piqray) in combination with fulvestrant (AstraZeneca’s Faslodex) for the treatment of postmenopausal women, as well as men, with hormone receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an …

Advanced Drug Delivery Systems Market Outlook To 2027 Key Companies Novartis AG, Pfizer, Inc., and Takeda Pharmaceutical Company Limited | 12/4/2019

Press Releases Advanced Drug Delivery Systems Market Outlook To 2027 Key Companies Novartis AG, Pfizer, Inc., and Takeda Pharmaceutical Company Limited “Global Advanced Drug Delivery Systems Market Analysis to 2027” is a specialized and in-depth study of the Advanced Drug Delivery Systems industry with a focus on the global market trend. The report aims to provide an overview of global Advanced Drug Delivery Systems market with detailed market segmentation …

Newly approved sickle cell drug ushers in an era of therapeutic breakthroughs - Entertainment & Life - telegram.com - Worcester, MA | 12/4/2019

… to make healthy red blood cells, with the goal of replacing sickled cells as they die off. Early results from a small group of patients are encouraging. Cost, as always, is a looming issue. Novartis said Adakveo will be priced at $2,357 per vial, so a year’s treatment would cost between about $84,000 and $113,000. Booker has personal experience with the cost barrier. She wanted to try Endari, but couldn’t …

The North America smart inhalers market is expected to reach US$ 3,749.90 Mn in 2027 from US$ 503.91 Mn in 2018 | PR Newswire | 12/4/2019

… the fastest growth rate during the forecast period, 2019 to 2027. Some of the major primary and secondary sources for smart inhalers included in the report are, GlaxoSmithKline plc, Adherium Ltd., Vectura Group plc, Novartis AG, Findair Sp. z o. o., Cohero Health, Crux Product Design Ltd, Teva Pharmaceuticals, 3M , Amiko Digital Health Limited, and others. //www.reportlinker.com/p05828399/?utm_source=PRN …

Global Hedgehog Pathway Inhibitors Market 2019 by Company, Regions, Type and Application, Forecast to 2024 | 12/4/2019

… Margin and Market Share (2017-2018) 2.2 Mayne Pharma Group 2.2.2 Hedgehog Pathway Inhibitors Type and Applications 2.2.2.1 Product A 2.2.3 Mayne Pharma Group Hedgehog Pathway Inhibitors Revenue, Gross Margin and Market Share (2017-2018) 2.3 Novartis 2.3.2 Hedgehog Pathway Inhibitors Type and Applications 2.3.2.1 Product A 2.3.3 Novartis Hedgehog Pathway Inhibitors Revenue, Gross Margin and Market Share (2017-2018) 2.4 Roche 2.4.2 Hedgehog Pathway Inhibitors Type and Applications 2.4.2.1 Product A 2.4.3 …

Global Cancer Immunotherapy Market Report 2020: Market Accounted for 50% o the Overall Oncology Drugs Market, Generating $75 Billion in 2019 and $115 Billion by 2023 | PR Newswire | 12/4/2019

… as IMAB362 for the treatment of solid cancers is also exciting. Other projects comparing CAR-T cell effectiveness against T-cells that target CD19 or mesothelin are interesting in a preclinical setting. Of course, Novartis gained the first CAR-T FDA approval for Kymriah (tisagenlecleucel, CTL019), in August 2017 , for children and young adults with B-cell ALL. In October 2017 , Yescarta (axicabtagene ciloleucel) from Kite Pharma for adult patients …

Global Triazolam Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 | 12/4/2019

… Sales, Price, Revenue, Gross Margin and Market Share (2017-2018) 2.2 Nhwa-group 2.2.2 Triazolam Type and Applications 2.2.2.1 Product A 2.2.3 Nhwa-group Triazolam Sales, Price, Revenue, Gross Margin and Market Share (2017-2018) 2.3 Novartis 2.3.2 Triazolam Type and Applications 2.3.2.1 Product A 2.3.3 Novartis Triazolam Sales, Price, Revenue, Gross Margin and Market Share (2017-2018) 2.4 Teva 2.4.2 Triazolam Type and Applications 2.4.2.1 Product A 2.4.3 Teva Triazolam Sales, Price …

Global Anti-infective Drugs Market Report 2019 with Forecasts to 2024, Led by Novartis, Merck & Co, Sanofi, GSK, and Gilead Sciences – ResearchAndMarkets.com | 12/4/2019

… channels as well as reaching out to each category of patients with different diseases and age groups, which makes the companies grow in this market. Some of the major players in the market are Novartis AG, Merck & Co., Inc, Sanofi SA, GSK, and Gilead Sciences, among others. Key Topics Covered …

Food and Drug Administration

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… America Europe Asia Pacific Middle East and Africa (MEA) South America Chapter 9 Regulatory Scenario Regulatory Challenges North America U.S. Food and Drug Administration (FDA) Europe Asia-Pacific Japan China South America Brazil Chapter 10 … CASI Pharmaceuticals Inc. Celgene Celldex Therapeutics Celsion Clovis Eli Lilly Novartis Pfizer Puma Biotechnology Roche Syndax Pharmaceuticals Tesaro Inc. Chapter 13 Competitive Landscape Major Mammography Equipment Market Players Major Breast Cancer Drug Market Players Chapter …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European Medicines Agency) ETH Zurich European Commission European Federation of Pharmaceutical …

Biotech

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … Crelux Critical Diagnostics Critical Path Institute (C-Path) [US] CTI Biotech Daiichi Sankyo Dako (now part of Agilent) Dana-Farber Cancer Institute [US] Danaher DaVita Labs DiaGenic Durin Technologies DxS (now part of QIAGEN) EKO …

Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI | 12/4/2019

… models because of the complexity of the human brain, according to Stemonix. Atomwise has struck a number of deals with biotech and pharma companies interested in its tech, including Atropos Therapeutics, Hansoh Pharma, and Eli … parts of cannabis, including cannabidiol and cannabidivarin, as potential treatments. Novartis (NYSE: NVS ) subsidiary AveXis is also advancing a gene therapy for Rett, but in August said that its advancement to human testing would be …

Gene Therapy

Top 8 Predictions That Will Disrupt Healthcare in 2020 | Forbes | 12/4/2019

… to enter early phase clinical trials in the next 12 to 18 months. Prediction 3: Annuity-based model to catapult gene therapy commercialization While the launch of UniQure ’s gene therapy Glybera created a lot … such as Cigna and CVS, leading gene therapy manufacturers like Novartis, Bluebird Bio, and Spark Therapeutics will continue to explore annuity-based specialized reimbursement programs to ease the burden of high out-of-pocket spending …

Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI | 12/4/2019

Novartis (NYSE: NVS ) subsidiary AveXis is also advancing a gene therapy for Rett, but in August said that its advancement to human testing would be delayed so it could redo and add to preclinical studies. The decision was made following revelations that some of the animal data the company submitted to the FDA in support of onasemnogene abeparvovec (Zolgensma), the gene therapy it developed for babies with spinal muscular atrophy …

Clinical Data

First Industry Datasets Submitted to ASH Research Collaborative Data Hub | PR Newswire | 12/4/2019

WASHINGTON , Dec. 4, The ASH Research Collaborative (ASH RC) has collaborated with two industry leaders, Novartis Pharmaceuticals Corporation (Novartis) and Amgen, to include de-identified patient data from three separate studies of nearly 500 patients … Hub, a platform designed to accelerate scientific discovery by gathering clinical data on rare blood diseases. Clinical trials are essential to identify new approaches to the prevention and treatment of hematologic diseases. People who take …

The return of the megamerger | 12/2/2019

… in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact. Novartis pays Takeda Pharmaceutical $3.4 billion to acquire the dry-eye treatment Xiidra. Pfizer merges … is less heady today, in part because the release of clinical data for hyped drug candidates is bringing values down to reality. Those same assets this year cost closer to $5 billion or $10 billion …

Big Pharma

Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon | 12/4/2019

Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon Novartis To Use Amazon’s Cloud Expertise To Improve Technical Ops 04 Dec 2019 Sten Stovall @stenstovall Executive Summary Novartis’s AI head tells Scrip an open-ended collaboration … against the drawn-out, asset-draining product cycles of today’s big pharma enterprise, then what is the secret of doing it well? In Vivo looks for answers in a conversation with Novartis strategy lead Stephen …

7 Exciting Biotech Stocks to Buy Now | 12/4/2019

… 7 Entertainment Stocks to Buy to Escape Holiday Blues At Growth Investor, we are focused on pure biotech stocks, not big pharma. These seven big biotech companies are driving cutting-edge therapies. These names are … with Pfizer (NYSE:PFE) for a drug targeting hemophilia. And Novartis (NYSE:NVS) has control of European marketing for Luxturna.The stock is up 184% year-to-date and has a bright future if it can …

Biosimilars

Bio-Thera Solutions Announces NMPA approval of IND Application to Initiate Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab) | 12/4/2019

… developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. The … Seiyaku Kabushiki Kaisha Corporation5 Cosentyx® is a registered trademark of Novartis AG6 Simponi® is a registered trademark of Johnson & Johnson Corporation Contacts …

Bio-Thera Solutions Announces NMPA approval of IND Application to Initiate Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab) | BioSpace | 12/4/2019

… developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. The … Kabushiki Kaisha Corporation 5 Cosentyx® is a registered trademark of Novartis AG 6 Simponi® is a registered trademark of Johnson & Johnson Corporation View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005310/en/ Contacts Bert …

Medicare

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European Medicines Agency …

Amid Multi-Billion-Dollar Deals, Panels Highlight Gene Therapy Challenges | 12/4/2019

… some cases, it’s easier to do that if you have a biomarker and you could pay for performance.” Avexis, a Novartis Company, she noted, has offered payers reimbursement models allowing them to pay for performance … the science is going.” Aitken said the U.S. Centers for Medicare and Medicaid Services (CMS), as the nation’s largest payer, should take a lead role in bringing stakeholders together to forge a consensus on gene …

Digital Health

Top 8 Predictions That Will Disrupt Healthcare in 2020 | Forbes | 12/4/2019

… Novartis, Bluebird Bio, and Spark Therapeutics will continue to explore annuity-based specialized reimbursement programs to ease the burden of high out-of-pocket spending by patients. Prediction 4: Continued VC funding mega-rounds make 2020 a banner year for Digital Health Unicorns’ IPO exits There are two reasons we expect increased IPO activity in the next 12 to 18 months. First, as of mid-year 2019, there are about …

The North America smart inhalers market is expected to reach US$ 3,749.90 Mn in 2027 from US$ 503.91 Mn in 2018 | PR Newswire | 12/4/2019

Novartis AG, Findair Sp. z o. o., Cohero Health, Crux Product Design Ltd, Teva Pharmaceuticals, 3M , Amiko Digital Health Limited, and others. //www.reportlinker.com/p05828399/?utm_source=PRN …

CAR-T

Global Cancer Immunotherapy Market Report 2020: Market Accounted for 50% o the Overall Oncology Drugs Market, Generating $75 Billion in 2019 and $115 Billion by 2023 | PR Newswire | 12/4/2019

… nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), Ibrance (palbociclib) the newly approved Bavencio (avelumab) and Imfinzi (durvalumab) and of course the first CAR-T therapies Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel).Opdivo (nivolumab) from BMS is one … or mesothelin are interesting in a preclinical setting. Of course, Novartis gained the first CAR-T FDA approval for Kymriah (tisagenlecleucel, CTL019), in August 2017 , for children and young adults with B-cell ALL. In …

Precision Medicine

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Top 8 Predictions That Will Disrupt Healthcare in 2020 | Forbes | 12/4/2019

… by the end of 2020. Alongside leading private insurance companies such as Cigna and CVS, leading gene therapy manufacturers like Novartis, Bluebird Bio, and Spark Therapeutics will continue to explore annuity-based specialized reimbursement programs … telehealth by adding more capabilities beyond the home. Prediction 7: Precision medicine-led approaches will pave the way for next-gen health data analytics solutions We believe, in the coming decade, cognitive analytic platforms capable …

Pfizer

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… analysis Profile descriptions of the key market leaders, including AbbVie Inc., Abbott Laboratories, Dako, Eli Lilly and Co., Nanostring Technologies, Pfizer Inc., Puma Biotechnology Inc., and Sanofi S.A. Key Topics Covered: Chapter 1 Introduction Study … CASI Pharmaceuticals Inc. Celgene Celldex Therapeutics Celsion Clovis Eli Lilly Novartis Pfizer Puma Biotechnology Roche Syndax Pharmaceuticals Tesaro Inc. Chapter 13 Competitive Landscape Major Mammography Equipment Market Players Major Breast Cancer Drug Market Players Chapter …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

PfizerNovartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market in 2029? • Who are the leading players and what …

Merck

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market in 2029? • Who are the leading players and what are …

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data | Globe Newswire | 12/4/2019

… Merck, and Novartis, AbbVie Inc., Acorda Therapeutics Inc. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market Segments covered in the report: For the purpose of this report, Reports and Data has segmented the Multiple Sclerosis Therapeutics market on the basis of product type, mode of administration type, distribution channel, and region: Product Type (Revenue, USD Million; 2016 …

GlaxoSmithKline

Contract manufacturing in “tremendous” state as growth strains current capacity, CPhI delegates told | 12/4/2019

… MA, US) noted Thermo Fisher Scientific’s acquisition of Brammer Bio LLC (Cambridge, MA, US) in March and a small molecule GlaxoSmithKline Plc (Brentford, UK) API site in Cork, Ireland in May. Jeremie Trochu, vice-president … Woburn, MA, US), a company that grew out of the Novartis-MIT Center for Continuous Manufacturing (Cambridge, MA, US), to develop machinery for continuous manufacturing, noted Miller. Continuous processing has challenges to adoption, Bikash Chatterjee …

Global Anti-infective Drugs Market Report 2019 with Forecasts to 2024, Led by Novartis, Merck & Co, Sanofi, GSK, and Gilead Sciences - ResearchAndMarkets.com | Business Wire | 12/4/2019

… and age groups, which makes the companies grow in this market. Some of the major players in the market are Novartis AG, Merck & Co., Inc, Sanofi SA, GSK, and Gilead Sciences, among others. Key Topics … 6.1.4 Bristol-Myers Squibb Company 6.1.5 Gilead Sciences Inc. 6.1.6 GlaxoSmithKline PLC 6.1.7 Merck & Co. Inc. 6.1.8 Novartis AG 6.1.9 Pfizer Inc. 6.1.10 Sanofi S.A. 7 MARKET OPPORTUNITIES AND FUTURE TRENDS For more information about …

Bristol-Myers Squibb

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

Novartis Pfizer Puma Biotechnology Roche Syndax Pharmaceuticals Tesaro Inc. Chapter 13 Competitive Landscape Major Mammography Equipment Market Players Major Breast Cancer Drug Market Players Chapter 14 Company Profiles Abbvie Inc. Abbott Laboratories Astrazeneca Plc Atossa Genetics Inc. Bristol-Myers Squibb Co. Dako Eli Lilly And Co. F. Hoffmann-La Roche Ag Nanostring Technologies Novartis International Ag Pfizer Inc. Puma Biotechnology Inc. Sanofi S.A. For more information about this report visit …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and …

Amgen

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … of Quintiles) Affymetrix Agendia Agilent Alacris Theranostics Alere Amarantus BioSciences Amgen Applied Biosystems (part of Life Technologies) Aptiv Solutions Arctic Partners ARIAD Pharmaceuticals Ariana Pharma Arizona State University Arrayit ARUP Laboratories AstraZeneca Athena Diagnostics (a …

Global Hematology Partnering Deal Trends, Players and Financials 2014-2019 | Globe Newswire | 12/4/2019

… Advanced Biological Laboratories AffaMed Therapeutics AkaRx Akebia Therapeutics Akers Biosciences Akron Biotechnology Alchemia Alnylam Pharmaceuticals Alphamedix American society of Hematology Amgen Anthos Therapeutics Antitope Apceth Aplagon ApoPharma Aptevo Therapeutics APT Therapeutics ArcherDX Arch Therapeutics Armaghan … Health National Transfusiology Center NCPC GeneTech New York Blood Center Novartis NovImmune Novo Nordisk Nxstage Medical Octapharma OMRF OrSense Ortho-Clinical Diagnostics Otsuka Oxford BioMedica Palex Medical Pan American Cancer Treatment Centers PathoQuest Pathway Diagnostics …

Sandoz

Novartis Associate Job Opening – BSc Biotech/Biochem/Biology Apply Online | 12/4/2019

Business Unit : Product Dev SZ Employment Type : Regular Job Description for Novartis Job: The key responsibility of this position is to ensure: Support DRC Manager/ Specialist for Regulatory filings/dossiers as per established development milestones … learned. Establish and maintain a sound working relationship with all Sandoz Regulatory affairs departments and also SDC groups. Support DRC manager/specialist for worldwide regulatory strategy for developments projects with a focus on creativity and …

Visiongain Report Offers Transformative Insights on the $11bn Biological Drug API Manufacturing Market | PR Newswire | 12/3/2019

PRNewswire/ – The biological drug API manufacturing market is estimated to grow at a CAGR of 9.5% in the first half of the forecast period. In 2018, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry . How this 211-page Visiongain report delivers: • Biological Drug API Manufacturing Services market forecast to 2029 • Biological Drug API Manufacturing Services market forecast to 2029 by Expression Systems …

AbbVie

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… drugs, blockbuster drugs, and other novel drugs development A relevant patent analysis Profile descriptions of the key market leaders, including AbbVie Inc., Abbott Laboratories, Dako, Eli Lilly and Co., Nanostring Technologies, Pfizer Inc., Puma Biotechnology … CASI Pharmaceuticals Inc. Celgene Celldex Therapeutics Celsion Clovis Eli Lilly Novartis Pfizer Puma Biotechnology Roche Syndax Pharmaceuticals Tesaro Inc. Chapter 13 Competitive Landscape Major Mammography Equipment Market Players Major Breast Cancer Drug Market Players Chapter …

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data | Globe Newswire | 12/4/2019

… Novartis, AbbVie Inc., Acorda Therapeutics Inc. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market Segments covered in the report: For the purpose of this report, Reports and Data has segmented the Multiple Sclerosis Therapeutics market on the basis of product type, mode of administration type, distribution channel, and region: Product Type (Revenue, USD Million; 2016–2026) Immunomodulators …

GSK

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market in 2029? • Who are the leading players and what are …

Global Anti-infective Drugs Market Report 2019 with Forecasts to 2024, Led by Novartis, Merck & Co, Sanofi, GSK, and Gilead Sciences - ResearchAndMarkets.com | Business Wire | 12/4/2019

Novartis AG, Merck & Co., Inc, Sanofi SA, GSK, and Gilead Sciences, among others. Key Topics Covered 1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Growing Prevalence of Targeted Diseases 4.2.2 Increased Awareness and Initiatives Against Infectious Diseases 4.2.3 Rise of Multi-drug Resistant Organisms 4.3 Market Restraints 4.3.1 High …

Bristol-Myers

Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2018 & 2019-2024 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

Novartis Pfizer Puma Biotechnology Roche Syndax Pharmaceuticals Tesaro Inc. Chapter 13 Competitive Landscape Major Mammography Equipment Market Players Major Breast Cancer Drug Market Players Chapter 14 Company Profiles Abbvie Inc. Abbott Laboratories Astrazeneca Plc Atossa Genetics Inc. Bristol-Myers Squibb Co. Dako Eli Lilly And Co. F. Hoffmann-La Roche Ag Nanostring Technologies Novartis International Ag Pfizer Inc. Puma Biotechnology Inc. Sanofi S.A. For more information about this report visit …

Contract manufacturing in “tremendous” state as growth strains current capacity, CPhI delegates told | 12/4/2019

… Maryland, US) in June 2019, Juniper Pharmaceuticals Inc (Boston, MA, US) in July 2018 and an Anagni, Italy facility from Bristol-Myers Squibb Co (NY, NY,US) in June. Both Brammer and Paragon are in … Woburn, MA, US), a company that grew out of the Novartis-MIT Center for Continuous Manufacturing (Cambridge, MA, US), to develop machinery for continuous manufacturing, noted Miller. Continuous processing has challenges to adoption, Bikash Chatterjee …

Biogen

Pharma Isn’t Eager To Carry Cures Act 2.0 Over Finish Line Despite Being Instrumental In Passage Of First Version | Kaiser Health News | 12/4/2019

… be protected from generic imitators in the U.S.-Mexico-Canada Agreement, or USMCA. (Mauldin, Andrews and Leary, 12/2) Reuters: Pfizer, Novartis Lead $2 Billion Spending Spree On Gene Therapy Production Eleven drugmakers led by Pfizer … across Connecticut on the affordability of medication. (Carlesso, 12/3) Stat: Biogen Strikes Value-Based Contracting Deal With UPMC Health In a twist on value-based contracting, a drug maker has agreed to offer a larger …

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data | Globe Newswire | 12/4/2019

Biogen Idec, Teva Pharmaceuticals, Bayer Healthcare, Pfizer, Sanofi-Aventis, Merck, and Novartis, AbbVie Inc., Acorda Therapeutics Inc. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market Segments covered in the report: For the purpose of this report, Reports and Data has segmented the Multiple Sclerosis Therapeutics market on the basis of product type, mode of administration type, distribution …

Jefferies Financial Group

Princeton Global Asset Management LLC Grows Position in Novartis AG (NYSE:NVS) | 12/4/2019

Princeton Global Asset Management LLC raised its stake in shares of Novartis AG (NYSE:NVS) by 4.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned … hold” rating in a research report on Saturday, October 19th. Jefferies Financial Group reissued a “buy” rating on shares of Novartis in a report on Thursday, August 29th. Finally, Cowen reissued a “buy” rating and …

State Street Corp Boosts Stock Position in Novartis AG (NYSE:NVS) | 12/4/2019

State Street Corp raised its stake in shares of Novartis AG (NYSE:NVS) by 1.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund … shares of Novartis in a report on Friday, October 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, August 29th. Finally, ValuEngine raised Novartis from a “sell …

Biogen Idec

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data | Globe Newswire | 12/4/2019

… Biogen Idec, Teva Pharmaceuticals, Bayer Healthcare, Pfizer, Sanofi-Aventis, Merck, and Novartis, AbbVie Inc., Acorda Therapeutics Inc. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market Segments covered in the report: For the purpose of this report, Reports and Data has segmented the Multiple Sclerosis Therapeutics market on the basis of product type, mode of administration type, distribution …

Alexandria Venture Investments

No. 458: Ink flows, Whoppers sizzle and cyber-defenders rise – plus, a critical organoid donation | 12/4/2019

Novartis Venture Fund, with participation from Evotec, M Ventures, Alexandria Venture Investments and other institutional investors. + Genvid Technologies , a NYC-based developer of interactive streaming technologies for game developers, media companies and sports broadcasters, raised $27 million in Series B funding led by New York’s Galaxy Interactive, March Capital Partners, OCA Ventures, Makers Fund and Horizons Ventures, as well as new investors Valor Equity Partners and K5 Global. BELOW THE …

Cancer Therapeutics Market Size to Reach US$ 176 Bn by 2026 | PR Newswire | 11/27/2019

… Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others. The key players of the cancer therapeutics market … Inc. launched with US$50 Mn in financing from 3SBio, Alexandria Venture Investments, 20/20 HealthCare Partners, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. The launch is intended to …

Alexandria Venture

No. 458: Ink flows, Whoppers sizzle and cyber-defenders rise – plus, a critical organoid donation | 12/4/2019

Novartis Venture Fund, with participation from Evotec, M Ventures, Alexandria Venture Investments and other institutional investors. + Genvid Technologies , a NYC-based developer of interactive streaming technologies for game developers, media companies and sports broadcasters, raised $27 million in Series B funding led by New York’s Galaxy Interactive, March Capital Partners, OCA Ventures, Makers Fund and Horizons Ventures, as well as new investors Valor Equity Partners and K5 Global. BELOW THE …

Cancer Therapeutics Market Size to Reach US$ 176 Bn by 2026 | PR Newswire | 11/27/2019

… Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others. The key players of the cancer therapeutics market … Inc. launched with US$50 Mn in financing from 3SBio, Alexandria Venture Investments, 20/20 HealthCare Partners, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. The launch is intended to …

Great Point Partners

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … Healthcare Genetic Technologies Geneva Bioinformatics (GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of …

Tergus Pharma to become full-fledged CDMO with new manufacturing facility | FiercePharma | 6/10/2019

… a manufacturing facility that will catapult it into the CDMO market. Tergus Pharma says an investment from private equity investor Great Point Partners will allow it to build its first commercial manufacturing facility. The Durham … company said. Terms of the deal were not disclosed. RELATED: Novartis finally unloads 300 troubled U.S. generics to India’s Aurobindo for $1B The investment comes as the dermatology market is undergoing big changes. Nestle last …

T. Rowe Price

Morning Edition: Commute cost ranking | ‘Fiduciary standard’ | Santander CEO | 5 Things | 12/3/2019

… Estate France vows EU retaliation against Trump digital tax plans Technology Harvard grad students plan to strike on Tuesday Education T. Rowe Price raised its stake in GE Banking & Financial Services AI startup hires new … Rating agencies have eye on Mass. budget stalemate Government & Regulations Novartis-linked biotech firm raises $56M for new spinouts Health Care With employees statewide, MassMutual’s Crandall backs a gas tax hike Banking & Financial Services View …

Global Viral Vectors, Non-Viral Vectors & Gene Therapy Manufacturing Market, 2019-2030 - Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA & Other Vectors | PR Newswire | 11/28/2019

Global Viral Vectors, Non-Viral Vectors & Gene Therapy Manufacturing Market, 2019-2030 - Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA & Other Vectors News provided by Research and Markets Nov 28, 2019, 08:45 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)” report has been added to ResearchAndMarkets.com’s offering. This …

SVB Leerink

The return of the megamerger | 12/2/2019

… of deal: Cholesterol-lowering drug in late-stage studies Source: Companies According to an analysis done by the investment firm SVB Leerink, global pharmaceutical merger and acquisition activity is on track to hit a 10 … 5.1 billion as part of a 10-year research pact. Novartis pays Takeda Pharmaceutical $3.4 billion to acquire the dry-eye treatment Xiidra. Pfizer merges its generic-drug business with Mylan to create a generics …

China gives Merck, BMS cold shoulder on reimbursement list as PD-1 battle enters new phase | FiercePharma | 12/2/2019

… an average 60.7% to win coverage in the world’s second-largest pharmaceutical market. AbbVie, AstraZeneca, Bayer, Gilead Sciences, Johnson & Johnson, Novartis, Roche and Sanofi are among multinational pharma companies to have reached deals with the … Wang told FiercePharma in an email interview. A team of SVB Leerink analysts also expressed caution over the long-term impact of Tyvyt’s low price, especially for that small a disease ahead of much larger …

Atlas Venture

IFM gets new CEO, bags another $55M to launch incubator, new subsidiaries | FierceBiotech | 12/2/2019

Novartis and enlisting the Big Pharma as a partner for another unit, the company is promoting its R&D chief Martin Seidel, Ph.D., to CEO and reeling in $55.5 million to fund more subsidiaries, including an incubator. The new funding, led by Omega Funds with Atlas Venture and Abingworth chipping in, will support its new incubator, IFM Discovery, as well as IFM Quattro, the company’s third subsidiary. The capital could …

IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer | PR Newswire | 12/2/2019

… select targets of the innate immune system – Financing is led by new investor Omega Funds, with participation from existing investors Atlas Venture and Abingworth – Dr. Gary D. Glick to transition to role of executive chairman … served as the Global Head of Strategic Alliances for the Novartis Institutes for Biomedical Research (NIBR), where he led a team responsible for creating collaborations with external partners to help advance NIBR’s mission. In that …

Blackstone Group

First Edition: December 2, 2019 | Kaiser Health News | 12/2/2019

… for information that she can share with Boston’s community of opioid users. (Bebinger, 11/27) NPR/ProPublica: Why TeamHealth, Owned By Blackstone Group, Stopped Suing Poor Patients After nine visits to the emergency room at Baptist … clue in scientists’ quest for a cure. (11/27) Reuters: Pfizer, Novartis Lead $2 Billion Spending Spree On Gene Therapy Production Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to …

Blackstone to invest $400 million in gene therapy venture with Ferring | 11/27/2019

… in gene therapy venture with Ferring Previous Post Blackstone to invest $400 million in gene therapy venture with Ferring (Reuters) – Blackstone Group Inc (BX.N) said on Monday it will invest $400 million in a joint … sciences unit, Blackstone has also formed a new company with Novartis AG (NOVN.S) to study a type of heart drug. Blackstone invested $250 million in that venture. NOVEMBER 25, 2019 …

Abingworth

IFM gets new CEO, bags another $55M to launch incubator, new subsidiaries | FierceBiotech | 12/2/2019

Novartis and enlisting the Big Pharma as a partner for another unit, the company is promoting its R&D chief Martin Seidel, Ph.D., to CEO and reeling in $55.5 million to fund more subsidiaries, including an incubator. The new funding, led by Omega Funds with Atlas Venture and Abingworth chipping in, will support its new incubator, IFM Discovery, as well as IFM Quattro, the company’s third subsidiary. The capital could …

IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer | PR Newswire | 12/2/2019

… the innate immune system – Financing is led by new investor Omega Funds, with participation from existing investors Atlas Venture and Abingworth – Dr. Gary D. Glick to transition to role of executive chairman News provided by … served as the Global Head of Strategic Alliances for the Novartis Institutes for Biomedical Research (NIBR), where he led a team responsible for creating collaborations with external partners to help advance NIBR’s mission. In that …

Harvard Medical School

Global Hematology Partnering Deal Trends, Players and Financials 2014-2019 | Globe Newswire | 12/4/2019

… Blood Disorder Foundation GNYHA Services Golden Meditech Government Scientific Source Greater New York Hospital Association Grifols Haemonetics Corporation HanAll Pharmaceuticals Harvard Medical School Healthcare Royalty Partners Helsinn Healthcare HemaCare Hemophilia Foundation of Southern California HEMORIO … Health National Transfusiology Center NCPC GeneTech New York Blood Center Novartis NovImmune Novo Nordisk Nxstage Medical Octapharma OMRF OrSense Ortho-Clinical Diagnostics Otsuka Oxford BioMedica Palex Medical Pan American Cancer Treatment Centers PathoQuest Pathway Diagnostics …

Global Hematology Partnering Deal Trends, Players and Financials 2014-2019 | Benzinga | 12/4/2019

… Blood Disorder Foundation GNYHA Services Golden Meditech Government Scientific Source Greater New York Hospital Association Grifols Haemonetics Corporation HanAll Pharmaceuticals Harvard Medical School Healthcare Royalty Partners Helsinn Healthcare HemaCare Hemophilia Foundation of Southern California HEMORIO … Health National Transfusiology Center NCPC GeneTech New York Blood Center Novartis NovImmune Novo Nordisk Nxstage Medical Octapharma OMRF OrSense Ortho-Clinical Diagnostics Otsuka Oxford BioMedica Palex Medical Pan American Cancer Treatment Centers PathoQuest Pathway Diagnostics …

Massachusetts General Hospital

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … Consortium (ICGC) Les entreprises du médicament (LEEM) [ France ] Malmö University Massachusetts General Hospital Max Planck Institute for Molecular Genetics [ Germany ] National Academy of Sciences National Cancer Institute (NCI) [US] National Health Service (NHS) [UK] National …

Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market | PR Newswire | 11/28/2019

… major players in the acute myeloid leukaemia market: • Bristol-Myers Squibb Company • Celgene • Clavis Pharma ASA • Daiichi Sankyo • Eisai • GSK • Novartis • Roche • Sunesis Pharmaceuticals • Teva • This report discusses factors that drive and restrain the acute … Legacy Emanuel Hospital & Health Center Mary Babb Randolph Cancer Center Massachusetts general Hospital Mayo Clinic MD Anderson Cancer Center Medical College of Wisconsin Cancer Center Medizinische Klinik und Poliklinik I Memorial Sloan Kettering Cancer Center …

Mayo Clinic

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … Leuven (University of Leuven) LabCorp Life Technologies LightArray Biotech M2Gen Mayo Clinic [US] Mayo Collaborative Services MDxHealth Medical Research Council [UK] MediMedia Pharma Solutions Memorial Sloan-Kettering Cancer Center [US] Merck & Co. Merck KGaA Metabolon …

Global Hematology Partnering Deal Trends, Players and Financials 2014-2019 | Globe Newswire | 12/4/2019

Mayo Clinic Medgenics Medial Medica MedImmune Meditrade Medline Industries Menarini Merus Labs International Metabasis Therapeutics MicroHealth Miraca Life Sciences Mitsubishi Tanabe Pharma Moberg Pharma National Center for Advancing Translational Sciences (NCATS) National Heart Lung and Blood Institute National Hemophilia Foundation National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health National Transfusiology Center NCPC GeneTech New York Blood Center Novartis NovImmune Novo Nordisk Nxstage Medical Octapharma OMRF …

Memorial Sloan Kettering Cancer Center

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and …

Milking It: Study in Mice Suggests Lactose in the Diet Feeds Dangerous Gut Bacteria | Memorial Sloan Kettering Cancer Center | 11/29/2019

… Seres Therapeutics and consulting fees from DaVolterra. Dr. van den Brink has received research support from Seres Therapeutics; has consulted, received honorarium from, or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, WindMIL Therapeutics, Merck & Co. Inc., Acute Leukemia Forum (ALF), and DKMS Medical Council (Board). He also has IP licensing with Seres Therapeutics and Juno Therapeutics and stock options from …

Beth Israel Deaconess Medical Center

Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart | 12/4/2019

Beth Israel Deaconess Medical Center also contributed to this study, which was supported by AVEO Oncology. Pal has received honoraria from and served as a consultant for Pfizer, Novartis, AVEO Oncology, Genentech, Exelixis, Bristol-Myers Squibb, Astellas, Eisai, Roche and Ipsen. About City of Hope City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope …

Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market | PR Newswire | 11/28/2019

… major players in the acute myeloid leukaemia market: • Bristol-Myers Squibb Company • Celgene • Clavis Pharma ASA • Daiichi Sankyo • Eisai • GSK • Novartis • Roche • Sunesis Pharmaceuticals • Teva • This report discusses factors that drive and restrain the acute … and White Research Institute Benaroya Research Institute at Virginia Mason Beth Israel Deaconess Medical Center Breslin Cancer Center Center for Blood Disorders and Stem Cell Transplantation Charles A. Sammons Cancer Center Columbia University Medical Dana …

National Jewish Health

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … Infectious Diseases (NIAID) [US] National Institute on Aging ( NIA) [US] National Jewish Health [US] Newcastle University [UK] NIH (National Institute of Health) Oslo University Hospital Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmaceuticals and Medical …

Living with Alpha-1 Antitrypsin Deficiency: Empowering Patients and Healthcare Professionals | 11/14/2019

… 4 Karen Skålvoll , 5 Robert A. Sandhaus , 1 A. Rembert Koczulla 6,7 Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado, USA Division of Pulmonary and Critical Care Medicine, Medical University … for CSL Behring, Kamada, Mereobiopharma, Vertex, Inhibrx, Polypharma, Z Factor, Novartis, Shire, GlaxoSmithKline, Akari, AstraZeneca and Covasin. Dr Zanichelli has been a consultant and/or speaker for CSL Behring and Shire. Prof Sandhaus is Medical …

University of Texas MD Anderson Cancer Center

The return of the megamerger | 12/2/2019

… in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact. Novartis pays Takeda Pharmaceutical $3.4 billion to acquire the dry-eye treatment Xiidra. Pfizer merges … He also has leadership and crisis experience: he steered the University of Texas MD Anderson Cancer Center out of financial and legal trouble, and while he was at the University of Pennsylvania, he took responsibility …

Calculating the Costs of Clinical Trials | 12/1/2019

… costs of trial participation can reach hundreds and thousands of dollars, according to a recent survey by researchers at the University of Texas MD Anderson Cancer Center. Of 105 patients who had been participating in … to fill that gap – but with considerable limitations. For example, Novartis has stated that it will include a post-trial access provision in all of its clinical trial protocols. And, when trial results show superiority …

The University of Texas MD Anderson Cancer Center

The return of the megamerger | 12/2/2019

… in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact. Novartis pays Takeda Pharmaceutical $3.4 billion to acquire the dry-eye treatment Xiidra. Pfizer merges … treatments. He also has leadership and crisis experience: he steered the University of Texas MD Anderson Cancer Center out of financial and legal trouble, and while he was at the University of Pennsylvania, he took …

Calculating the Costs of Clinical Trials | 12/1/2019

… personal costs of trial participation can reach hundreds and thousands of dollars, according to a recent survey by researchers at the University of Texas MD Anderson Cancer Center. Of 105 patients who had been participating … to fill that gap – but with considerable limitations. For example, Novartis has stated that it will include a post-trial access provision in all of its clinical trial protocols. And, when trial results show superiority …

Cleveland Clinic

Calculating the Costs of Clinical Trials | 12/1/2019

… clinical trial sponsors are pledging to provide access to drugs to fill that gap – but with considerable limitations. For example, Novartis has stated that it will include a post-trial access provision in all of … Clinical News and director of the Leukemia Program at the Cleveland Clinic, recalled the devastating moment experienced by many patients when, “after devoting themselves to the trial requirements and jeopardizing their own health for the …

Memorial Sloan Kettering

Milking It: Study in Mice Suggests Lactose in the Diet Feeds Dangerous Gut Bacteria | Memorial Sloan Kettering Cancer Center | 11/29/2019

… which immune cells from the donor’s stem cells attack the recipient’s organs. Now, an international team led by scientists from Memorial Sloan Kettering has shown for the first time that foods containing lactose, a sugar … or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, WindMIL Therapeutics, Merck & Co. Inc., Acute Leukemia Forum (ALF), and DKMS Medical Council (Board). He also has …

Triplet Active in Anti-HER2-Exposed Metastatic Breast Ca | 11/29/2019

… treatment with the triplet regimen of trastuzumab (Herceptin) plus pertuzumab and gemcitabine (95% CI 61.5%-87.5%), Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues reported in JAMA Network … at a single center. Iyengar reported receiving personal fees from Novartis. Other investigators reported multiple conflicts of interest which are listed in the publication. 2019-11-29T12:00:00-0500 Primary Source JAMA Network Open …

UPMC Health Plan

Pharma Isn’t Eager To Carry Cures Act 2.0 Over Finish Line Despite Being Instrumental In Passage Of First Version | Kaiser Health News | 12/4/2019

… be protected from generic imitators in the U.S.-Mexico-Canada Agreement, or USMCA. (Mauldin, Andrews and Leary, 12/2) Reuters: Pfizer, Novartis Lead $2 Billion Spending Spree On Gene Therapy Production Eleven drugmakers led by Pfizer … based on outcomes that patients report. In this instance, the UPMC Health Plan will pay less for two Biogen (BIIB) drugs — Tecfidera and Avonex — if patients say the medicines failed to help them, based on …

Drugmakers Betting Big On Gene Therapy By Investing Combined $2B Into Manufacturing Pricey Treatments | Kaiser Health News | 12/2/2019

And Pfizer and Novartis are leading the pack. The risks involved with drugmakers building their own manufacturing plants are big but so are the potential rewards. In other pharmaceutical news: a high-stakes bet on … based on outcomes that patients report. In this instance, the UPMC Health Plan will pay less for two Biogen (BIIB) drugs — Tecfidera and Avonex — if patients say the medicines failed to help them, based on …

Aetna

We spoke to the execs tasked with bringing technology to some of the world’s oldest healthcare companies. Here’s how they’re picking their spots. | Business Insider | 12/3/2019

… ways to enhance drug discovery and development, to better connecting with consumers. We spoke to the CDOs at CVS Health, Novartis, and Pfizer about their priorities. Subscribe to Dispensed, Business Insider's weekly healthcare … came into his role in 2016 as a part of Aetna, the massive health insurer CVS acquired in 2018. CVS is a $98 billion company that provides insurance to 39 million people and operates nearly …

ICER Will Take Different Approach to Assess Short-Term, High-Impact Products | 12/2/2019

… heads with their high costs. In May, the FDA approved gene therapy Zolgensma (onasemnogene abeparvovec-xioi) from AveXis, Inc., a Novartis AG unit, to treat spinal muscular atrophy (SMA), an often-fatal condition (SMA 7/1/19 … OptumRx. CVS Health, which owns CVS Caremark PBM, purchased insurer Aetna late last year in a $69 billion deal, while insurer Cigna finalized its $54 million purchase of Express Scripts Holding Co. in late December …

Indian Health Service

Health Care Reform Articles - November 25, 2019 | 11/26/2019

… will close the revolving door between health care lobbyists and government, and end the practice of large pharmaceutical companies like Novartis, United Health, Roche, Pfizer, and Merck vacuuming up senior government officials to try and … workforce. I will expand the National Health Service Corps and Indian Health Service loan repayment program to allow more health professionals – including physicians, physician assistants, registered nurses, nurse practitioners, and other licensed practitioners – to practice …

Warren Lays Out A 3 Year Plan To Transition To Medicare For All | 11/16/2019

… will close the revolving door between health care lobbyists and government, and end the practice of large pharmaceutical companies like Novartis, United Health, Roche, Pfizer, and Merck vacuuming up senior government officials to try and … workforce. I will expand the National Health Service Corps and Indian Health Service loan repayment program to allow more health professionals – including physicians, physician assistants, registered nurses, nurse practitioners, and other licensed practitioners – to practice …

Clover Health

Alignment Healthcare bucked the net loss trend among its peers’ financial performance | Business Insider | 11/20/2019

… same time frame last year, according to Business Insider Prime. BI Prime raked through the financial results of Oscar Health, Clover Health, Bright Health, Devoted Health, and Alignment Healthcare — which were the targets of heavy … benefits to the new healthcare technology Biofourmis teams up with Novartis to commercialize a digital therapeutics platform for heart failure patients A genetic testing firm launched an atrial fibrillation research app on Apple devices …

Measuring Digital Health Maturity: Review of the Top 10 Pharma Activity 2014-2019 | PR Newswire | 10/26/2019

… more research partnerships than commercial. Digital health related partnership activity across the board has increased almost 5 fold since 2014 Novartis has the most digital health partnerships publicly announced since 2014 Investments and Acquisitions Digital … Abbott Abbvie Akili Almirall Applied VR Bayer Bigfoot BMS Bupa Clover health GlucoMe GSK GuideWell Health Beacon IBM Imperial College Health Partners J&J Livongo Merck MySugr Noona Novartis NovoAir OneDrop Owlstone Partners Healthcare Pfizer …

Humana

High-Paying, Flexible Jobs In 2020: The Top 40 Companies To Watch | Forbes | 11/19/2019

… freelance gigs in Marketing, Data Entry and HR. They also have quite a few open offers for content writers . 15. Humana – another healthcare services provider who’s embracing the concept of remote work. The current openings … training programs. Mostly, they hire remotely for teaching positions. 32. Novartis is a renowned global pharmaceutical and healthcare research company. They are frequently publishing remote jobs for sales specialists and account coordinators. 33. Philips . The …

Warren Lays Out A 3 Year Plan To Transition To Medicare For All | 11/16/2019

… will close the revolving door between health care lobbyists and government, and end the practice of large pharmaceutical companies like Novartis, United Health, Roche, Pfizer, and Merck vacuuming up senior government officials to try and … entities. That would block major industry players like UnitedHealth , Anthem , Humana , CVS Health , Pfizer, Amgen , AbbVie , Eli Lilly , Gilead , and Novartis – along with any trade associations that receive money from them – from spending to influence …

Harvard Pilgrim Health Care

How A Computer Model Prices the Value Of Good Health and Moderates Drug Costs | 11/7/2019

… prices , including from the Trump administration and Democratic presidential candidates such as Elizabeth Warren, pharmaceutical companies have started paying attention. Novartis AG set the price of its lifesaving gene therapy Zolgensma at the limit suggested … that use QALYs. Michael Sherman, chief medical officer of insurer Harvard Pilgrim Health Care, welcomes ICER’s perspective. “We are [already] putting a price on a year of life,” he says. “We just let the pharmaceutical …

Katerina Sudit Joins Hill Holliday’s Trilia as Chief Media Officer | Business Wire | 11/5/2019

… game-changing ideas for such industry leaders as Bank of America, Party City, Capella University, Optum, Boar’s Head, Simple Mobile, Novartis, Cracker Barrel, Bayer and Frontier Communications. For more about our people, our work, and … results. Trilia’s clients include Santander Bank, Tempur Sealy, Capella University, Harvard Pilgrim Health Care, Party City, Robert Half and Frontier Communications. For more about Trilia, please visit http://www.triliamedia.com . View source version on businesswire.com : https …

UnitedHealthcare

Tech giants like Google and Amazon are beefing up their healthcare strategies. Here’s how 7 tech titans plan to tackle the $3.5 trillion industry. | Business Insider | 11/3/2019

… using data from the watch and other Apple devices in studies . Apple’s also been working with insurers like Aetna and UnitedHealthcare . In the case of Aetna, the program is wagering that an app and an … high-profile partnerships with the likes of companies like Walgreens , Novartis , Humana, and West Coast-based health system Providence St. Joseph Health . In addition to providing cloud services, Microsoft also commits to working with its …

Behavioral health providers affiliate to aid in transition to value-based payments | Crain’s New York Business | 10/30/2019

… Novartis, SAP and Urban Outfitters. Henry is in-network for major dental plans such as Aetna, Cigna, Delta Dental and UnitedHealthcare. Its services are billed to those insurers at no extra cost to employers. The company is able to perform preventive and restorative dentistry, such as fillings, and its dentists and hygienists are employees. Clinicians return to offices multiple times a year to establish a relationship with patients. A patient …

Cigna

Second IVIg course in Guillain-Barre syndrome with poor prognosis: the non-randomised ISID study | BMJ | 11/1/2019

Cigna HealthManagement, CSL Behring, DP Clinical, Grifols, Hansa Medical, Karos Pharmaceuticals, Neurocrine Biosciences, Novartis, Octapharma, Pharnext, Seattle Genetics, Sun Pharmaceuticals, and Syntimmune. He is on the data and safety monitoring board for Sanofi, Pledpharma, Pfizer, Johnson Roche, Sanofi Genzyme, Teva,TG Therapeutics and UCB. GC has received honoraria from CSL Behring. BCJ has received funding for research projects from Prinses Beatrix Spierfonds, Horizon 2020,GBS-CIDP Foundation International, Grifols, CSL …

Thursday, October 31, 2019 | Kaiser Health News | 10/31/2019

… billion in fiscal year 2018. (Brady, 10/30) Modern Healthcare: Texas Awards Nearly $10 Billion In Medicaid Contracts Health insurers Anthem, Cigna Corp. and Molina Healthcare stand to lose millions in premium revenue after losing ground … as more expensive brand-name drugs. (10/30) And in Reuters: Novartis’ Zolgensma Study Halted By FDA Amid Safety Questions U.S. regulators have halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety …

Health Net

Second IVIg course in Guillain-Barre syndrome with poor prognosis: the non-randomised ISID study | BMJ | 11/1/2019

… MD (Buffalo General Medical Center, Buffalo NY, USA); C.L. Sommer, MD (Universitätsklinikum Würzburg, Würzburg, Germany); J.D. Varrato, DO (Lehigh Valley Health Network, Allentown, USA); J. Verschuuren, MD, PhD (Leiden University Medical Centre, Leiden, The Netherlands … Behring, DP Clinical, Grifols, Hansa Medical, Karos Pharmaceuticals, Neurocrine Biosciences, Novartis, Octapharma, Pharnext, Seattle Genetics, Sun Pharmaceuticals, and Syntimmune. He is on the data and safety monitoring board for Sanofi, Pledpharma, Pfizer, Johnson Roche, Sanofi …

Behavioral health providers affiliate to aid in transition to value-based payments | Crain’s New York Business | 10/30/2019

Reprints Print Advanced Health Network and Recovery Health Solutions—independent practice associations recently awarded state funding as behavioral health care collaboratives—have entered a strategic affiliation. The result is a comprehensive behavioral health network across … Jersey, New York and Pennsylvania. Its clients include Audible, Comcast, Novartis, SAP and Urban Outfitters. Henry is in-network for major dental plans such as Aetna, Cigna, Delta Dental and UnitedHealthcare. Its services are billed …

Molina Healthcare

Thursday, October 31, 2019 | Kaiser Health News | 10/31/2019

… year 2018. (Brady, 10/30) Modern Healthcare: Texas Awards Nearly $10 Billion In Medicaid Contracts Health insurers Anthem, Cigna Corp. and Molina Healthcare stand to lose millions in premium revenue after losing ground in the Texas … as more expensive brand-name drugs. (10/30) And in Reuters: Novartis’ Zolgensma Study Halted By FDA Amid Safety Questions U.S. regulators have halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety …

Friday, August 23, 2019 | Kaiser Health News | 8/23/2019

… six new states, including Pennsylvania and Georgia, to its current roster of nine. Insurers including Cigna Corp. , Bright Health Inc., Molina Healthcare Inc. and Centene Corp. , the biggest seller of ACA plans, also plan larger … treat. (Rorhich, 8/22) The Wall Street Journal: FDA Focuses On Novartis Delay In Reporting Drug-Test Data Manipulation Federal regulators examining test data manipulation for a gene-therapy drug made by Novartis AG are zeroing …

Vas Narasimhan

Pharma Isn’t Eager To Carry Cures Act 2.0 Over Finish Line Despite Being Instrumental In Passage Of First Version | Kaiser Health News | 12/4/2019

… be protected from generic imitators in the U.S.-Mexico-Canada Agreement, or USMCA. (Mauldin, Andrews and Leary, 12/2) Reuters: Pfizer, Novartis Lead $2 Billion Spending Spree On Gene Therapy Production Eleven drugmakers led by Pfizer … Hinges On Succeeding Where Rivals Struggle Novartis AG Chief Executive Vas Narasimhan has spent the past two years buying up cutting-edge science. His latest deal is a high-stakes bet that the Swiss health …

We spoke to the execs tasked with bringing technology to some of the world’s oldest healthcare companies. Here’s how they’re picking their spots. | Business Insider | 12/3/2019

… ways to enhance drug discovery and development, to better connecting with consumers. We spoke to the CDOs at CVS Health, Novartis, and Pfizer about their priorities. Subscribe to Dispensed, Business Insider's weekly healthcare … Novartis Embedding technology into the company is something Novartis CEO Vas Narasimhan has been pushing since stepping into the role in 2018. Novartis is a $226 billion Swiss pharmaceutical giant known for its heart drugs …

Sara Peerun

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… new report today you stay better informed and ready to act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-biomarkers … in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving …

Visiongain Report Offers Transformative Insights on the $11bn Biological Drug API Manufacturing Market | PR Newswire | 12/3/2019

… market forecast to 2029 • Biological Drug API Manufacturing Services market forecast to 2029 by Expression Systems: • Mammalian cell culture • Microbial fermentation • Other expression platforms To request sample pages from this report please contact Sara Peerun at or refer to our website: https://www.visiongain.com/report/biological-drug-api-manufacturing-services-world-industry-and-market-forecast-to-2029/ download_sampe_div • Biological Drug API Manufacturing Services market forecast to 2029 by Therapeutic …

Peter Lynch

Bayer and Teva Double Down on Worst M&A Deals of Decade | 12/4/2019

… business. The reasons the 15 deals listed in the article didn’t work out included failed product launches and legal problems. Peter Lynch Chart of BAYN Bayer’s other big swing and miss was the 2014 acquisition … wasn’t the only company that whiffed on a consumer acquisition. Novartis ( NYSE:NVS ), Merck KGaA, Bristol-Myers Squibb ( NYSE:BMY ) and Pfizer ( NYSE:PFE ) each sold off all or pieces of their consumer businesses in …

Evotec Expands Strategic Partnership With Celmatix In Women’s Health - GuruFocus.com | 12/3/2019

… like oncology.” 4 Warning Signs with OTCPK:EVTCY. OTCPK:EVTCY 30-Year Financial Data The intrinsic value of OTCPK:EVTCY Peter Lynch Chart of OTCPK:EVTCY No financial terms of this collaboration were disclosed. ABOUT … term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec . FORWARD LOOKING STATEMENTS …

Mark Timney

Presented Without Comment | 12/4/2019

… management enrichment, you’re just not paying attention. CEO Named in Opioid Lawsuits to Reap $68 Million for Year’s Work [ Bloomberg ] “Mark Timney faces the kind of allegations that can end careers. The former Purdue Pharma … lowering treatment for cardiovascular disease. Last week, Swiss pharmaceutical giant Novartis AG agreed to buy it in a $9.7 billion deal that’s expected to be completed early next year. Timney’s stock options and small stake …

How FDA and Oncology Industry are Making Joint Efforts to Utilize Accelerated Approval Pathways for Cancer Drugs | PR Newswire | 11/26/2019

… unanimously rejected the proposal. The Medicines Company (NASDAQ: MDCO ) recently announced that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash … for patients and to maximize value for our shareholders,” said Mark Timney , Chief Executive Officer of The Medicines Company. “We are excited that millions of patients with atherosclerotic cardiovascular disease and familial hypercholesterolemia will potentially …

Melinda Gates

Global Hematology Partnering Deal Trends, Players and Financials 2014-2019 | Globe Newswire | 12/4/2019

… Baxalta Baxter International Bayer Bayer Healthcare Baylor College of Medicine Beijing Leadman Biochemistry Belgian Red Cross Bicycle Therapeutics Bill and Melinda Gates Foundation Biocept BIOCORP bioCSL Biogen BioMatrix Specialty Pharmacy Biomedical Advanced Research and Development … Health National Transfusiology Center NCPC GeneTech New York Blood Center Novartis NovImmune Novo Nordisk Nxstage Medical Octapharma OMRF OrSense Ortho-Clinical Diagnostics Otsuka Oxford BioMedica Palex Medical Pan American Cancer Treatment Centers PathoQuest Pathway Diagnostics …

Global Hematology Partnering Deal Trends, Players and Financials 2014-2019 | Benzinga | 12/4/2019

… Baxalta Baxter International Bayer Bayer Healthcare Baylor College of Medicine Beijing Leadman Biochemistry Belgian Red Cross Bicycle Therapeutics Bill and Melinda Gates Foundation Biocept BIOCORP bioCSL Biogen BioMatrix Specialty Pharmacy Biomedical Advanced Research and Development … Health National Transfusiology Center NCPC GeneTech New York Blood Center Novartis NovImmune Novo Nordisk Nxstage Medical Octapharma OMRF OrSense Ortho-Clinical Diagnostics Otsuka Oxford BioMedica Palex Medical Pan American Cancer Treatment Centers PathoQuest Pathway Diagnostics …

Adam Feuerstein

Amid Multi-Billion-Dollar Deals, Panels Highlight Gene Therapy Challenges | 12/4/2019

… some cases, it’s easier to do that if you have a biomarker and you could pay for performance.” Avexis, a Novartis Company, she noted, has offered payers reimbursement models allowing them to pay for performance … predicted. “But right now, that’s very unclear.” When panel moderator Adam Feuerstein, STAT senior writer, biotech, cited another challenge to gene therapy development—the small number of patients assessed in clinical trials for new treatments …

Novartis’ Zolgensma gene therapy study halted on animal safety concerns | STAT | 10/30/2019

Biotech Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns By Adam Feuerstein @adamfeuerstein October 30, 2019 DOMINICK REUTER/AFP/Getty Images T he Food and Drug Administration has halted a clinical trial of Novartis’ Zolgensma gene therapy due to a safety concern found in an animal study, the company said Wednesday. The hold affects the Novartis ( NVS ) clinical trial known as STRONG, which was testing a …

Christopher Raymond

Astellas inks $3B Audentes buyout to expand in gene therapy | FierceBiotech | 12/3/2019

… to establish a presence in the emerging sector. Astellas is the latest in a growing list of companies to see gene therapies in their future. Over the past two years, companies including Biogen, Novartis and Roche have struck deals to add gene therapies and associated infrastructure, driving up the value of other startups active in the field. The takeover of Audentes is expected to close in the first quarter of …

Where to Buy Booming Biotech ETFs | 12/3/2019

… week in a row in which biotech funds saw withdrawals exceed inflows, according to research conducted by Piper Jaffray analyst Christopher Raymond, as reported by Barron’s . As the melt-up in biotechs has continued in … acquisition of The Medicines Company ( MDCO ) by Swiss pharmaceutical giant Novartis AG ( NVS ), have also helped create industry buzz over the period. Below, we take a more detailed look at XBI and two other biotechnology …

Paul Hudson

Fortune Global Forum: A Different Point of View | 12/2/2019

… enjoy these presentations. She mentions something about digitalizing medical data, which is a bit over my head. The CEO of Novartis also discusses recreating medicines, which does not seem to really apply to me, as … people and machines. Shunee seems very interested in what CEO Paul Hudson of Sanofi had to say. He says that we all need to let go of our prejudices towards certain concepts, and look at …

Sanofi strategy exec Mansuri jumps ship ahead of new CEO’s big reveal | FiercePharma | 11/22/2019

… Sanofi’s strategy and business development head since 2016, is retiring at the end of the month. (Sanofi) New Sanofi CEO Paul Hudson is days away from unveiling his plans for the French drugmaker, but the … Dec. 10 in Cambridge, Massachusetts. Since he joined Sanofi from Novartis at the beginning of September, Hudson has been touring Sanofi’s facilities to learn as much about the company as possible. He’s also been reviewing …

Bernie Sanders

First Edition: December 2, 2019 | Kaiser Health News | 12/2/2019

… who had excited liberals when she initially embraced a Medicare-for-all idea first proposed by rival presidential candidate Sen. Bernie Sanders (I-Vt.), was suggesting a more centrist idea: to delay enactment of the … clue in scientists’ quest for a cure. (11/27) Reuters: Pfizer, Novartis Lead $2 Billion Spending Spree On Gene Therapy Production Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to …

The problem of manipulated data | 12/2/2019

How does data manipulation come about and what can be done to prevent it? Credit: Pixabay. In August, Novartis came under fire for submitting manipulated data in an application to the FDA. The problem lay … rush its product to market,” stated the politicians, who included Bernie Sanders and Elizabeth Warren. “Anything short of a forceful response would signal a green light to future pharmaceutical misbehavior.” Questions remain about who knew …

Elizabeth Warren

First Edition: December 2, 2019 | Kaiser Health News | 12/2/2019

… That is humbling in all the best ways.” (Anthony, 12/2) The Washington Post: How A Fight Over Health Care Entangled Elizabeth Warren — And Reshaped The Democratic Presidential Race In mid-November, a few dozen of … clue in scientists’ quest for a cure. (11/27) Reuters: Pfizer, Novartis Lead $2 Billion Spending Spree On Gene Therapy Production Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to …

The problem of manipulated data | 12/2/2019

How does data manipulation come about and what can be done to prevent it? Credit: Pixabay. In August, Novartis came under fire for submitting manipulated data in an application to the FDA. The problem lay … to market,” stated the politicians, who included Bernie Sanders and Elizabeth Warren. “Anything short of a forceful response would signal a green light to future pharmaceutical misbehavior.” Questions remain about who knew what, and why …